Efficiency of molecular GeneXpert MTB/RIF system and conventional test as rapid detection of TB associated lung cancer


Lung cancer is main cause of morbidity and mortality; it includes 12.4% of all new cancer cases, and about 29% of all cancer deaths. There is evidence about persons infected with tuberculosis have increased lung cancer risk. GeneXpert System new diagnostic technique firstly, for TB infection secondly, detect RIF –based rpoB gene mutations related resistance tuberculosis. The rapid detection allows the doctors take critical decisions about therapy. This study aimed to find relationship between lung cancer and TB using GeneXpert MTB/RIF assay compared to conventional Z-N stain. 50 cases suspected cancer was enrolled to procedure of Cephid GeneXpert system manufacture also conventional stain was done for all samples. Out of 33 positive lung cancer, 7 (21.22%) MTB/Rif sensitive was positive detected. Significant difference (p-value 0.0001**) was found between detected MTB/Rif (sensitive and resist) and not detected MTB/Rif by Molecular gen expert method. In addition, Z-N stain was positive in 6 (18.18%) BAL cancer cases. In lung cancer cases, there is no significant difference (p-value 0.828) between two rapid methods. Present study data showed the high percentage of M. tuberculosis/RIF sensitive in cancer bronchoalveolar lavage. Gene Xpert had a higher diagnostic yield in patients beside the routine work to diagnosis and detection of TB/ RIF related rpoB gene mutation as a cancer risk factor.


  • Amir MHA, Ali S, Hamid A, Mojtaba M, et al. (2013) The Study of Mycobacterium tuberculosis in Iranian Patients with Lung Cancer. Jundishapur J Microbiol. 6(3): 237-241.
  • Ashok R, Awdhesh K, Nishat A (1998) Multidrug-Resistant Mycobacterium tuberculosis: Molecular Perspectives. Emerging Infectious Diseases 4(2): 195-209.
  • Blakemore R, Story E, Helb D, Kop J, et al. (2010) Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol. 48: 2495-2501.
  • Carey JM, Greer AE (1958) Bronchogenic carcinoma complicating pulmonary tuberculosis: a report of eight cases and a review of140 cases since 1932. Ann Intern Med. 49: 161-180.
  • Cepheid GeneXpert MTB/RIF manual (2011).
  • Chen-Yi W, Hsiao-Yun H, Cheng-Yun P, et al. (2011) Pulmonary Tuberculosis Increases the Risk of Lung Cancer: A Population-Based Cohort Study. Cancer 117: 618-624.
  • Dheda K, Booth H, Huggett JF, Johnson MA, Zumla A, Rook GA (2005) Lung remodeling in pulmonary tuberculosis. J Infect Dis. 192: 1201-1209.
  • Ethiopian Public Health Institute (2014) Implementation Guideline for GeneXpert MTB/RIF Assay in Ethiopia, Addis Ababa.
  • Feld R, Bodey GP, Groschel D (1976) Mycobacteriosis in patients with malignant disease. Arch Intern Med. 136: 67-70.
  • Francis J. Curry (2008) Drug-Resistant Tuberculosis, A Survival Guide for Clinicians, 2nd Edition.
  • Goli A, Shamiri A, Khosroyar S, Talaiekhozani A, Sanaye R, Azizi K (2019) A review on different aerobic and anaerobic treatment methods in dairy industry wastewater. Journal of Environmental Treatment Techniques, 6(1): 113-141.
  • Josiane M, Estelle M, Francis N (2018) Effect of Substrates on Nutritional Composition and Functional Properties of Pleurotus Ostreatus. Current Research in Agricultural Sciences, 5(1): 15-22.
  • Li S, Liu B, Peng M, et al. (2017) Diagnostic accuracy of Xpert MTB/RIF for tuberculosis detection in different regions with different endemic burden: a systematic review and meta-analysis. PLoS One 12: e0180725.
  • Liang HY, Li XL, Yu XS, et al. (2009) Facts and fiction of the relationship between pre-existing tuberculosis and lung cancer risk: a systematic review. Int J Cancer 125: 2936-2944.
  • Libshitz HI, Pannu HK, Elting LS, Cooksley CD (1997) Tuberculosisin cancer patients: an update. J Thorac Imaging. 12: 41-46.
  • Lin WW, Karin M (2007) A cytokine-medicated link between innate immunity, inflammation, and cancer. J Clin Invest. 117: 1175-1183.
  • Morris SL, Bai Gh, Suffys P, Portillo-Gomez L, et al. (1995) Molecular mechanisms of multidrug resistance in clinicallisolates of Mycobacterium tuberculosis. J Infect Dis. 171: 954-960.
  • Opota O, Zakham F, Mazza-Stalder J, et al. (2019) Added Value of Xpert MTB/RIF Ultra for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting. J Clin Microbiol. 57(2): e01717-18
  • Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin. 55: 74-108.
  • Pesut DP, Marinkovic DM (2009) Lung cancer and pulmonary tuberculosis-A comparative population-genetic study British. J Med Genetics 12: 45-52.
  • QA Committee (2018) Mycobacterium tuberculosis Rifampicin resistance PCR by Cepheid GeneXpert: Annual Review. University health network / Mount Sinai Hospital.
  • Rieder HL (2002) Interventions for Tuberculosis Control and Elimination. Paris: International Union against Tuberculosis and Lung Disease.
  • Rufai SB, Kumar P, Singh A, et al. (2014) Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-Monoresistant mycobacterium tuberculosis. J Clin Microbiol. 52: 1846-1852.
  • Saulius C, Vladislavas V (2007) Lung cancer in patients with tuberculosis. World Journal of Surgical Oncology 5: 22.
  • Weitzman SA, Gordon LI (1990) Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 76: 655-663.
  • WHO (2007) Global tuberculosis control. Surveillance. Planning. Financing, WHO Report 2007. World Health Organization, Geneva.
  • WHO (2008) Anti-tuberculosis resistance in the world: fourth global report. WHO/HTM/TB/2008. World Health Organization, Geneva.
  • WHO (2011) Tuberculosis Prevalence Surveys: a Handbook. World Health Organization, Geneva.
  • WHO (2014) Xpert MTB/RIF implementation manual: Technical and operational ‘how-to’: practical considerations. France.
  • Wu CY, Hu HY, Pu CY, et al. (2011) Aerodigestive tract, lung and haematological cancers are risk factors for tuberculosis: an 8-yearpopulation-based study. Int J Tuberc Lung Dis. 15: 125-130.
  • Yang-Hao Y, Chien-Chang L, Wu-Huei H, et al. (2011) Increased Lung Cancer Risk among Patients with Pulmonary Tuberculosis A Population Cohort Study. Journal of Thoracic Oncology 6(1): 32-37.
  • Youness M, Elmostafa B, Nadia E-M, et al. (2019) Evaluation of GeneXpert MTB/RIF system performances in the diagnosis of extrapulmonary tuberculosis. BMC Infectious Diseases 19: 1069.


This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.